Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Cielo vs FuturHealth

Cielo
Graded #127

Higher grade

vs+3.8000000000000114
FuturHealth
Graded #219

Lower grade

The verdict

Cielo takes it — 69.4/100 to 65.6/100.

Cielo grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Cielo is a compounded-GLP-1-only telehealth platform offering semaglutide and tirzepatide with no brand-name drugs and no TRT, hair, or mental-health add-ons — a focused, single-purpose alternative to…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCielo +16
76
60
Dose & formulationCielo +4
85
81
Clinical oversightCielo +12
79
67
Labs & monitoringFuturHealth +8
53
61
FulfillmentCielo +5
67
62
Contract termsFuturHealth +35
20
55
Cielo · left barFuturHealth · right bar

The numbers

MetricCieloFuturHealth
WeighScore69.4/10065.6/100
GradeCC
Scorecard rank#127#219
Semaglutide$149/mo (all doses, compounded)$199/mo (compounded)
Tirzepatide$249/mo (all doses, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Cielo

Graded #127 · C

Strengths

  • Among the lowest 3-month bundle prices in compounded GLP-1 ($115/mo semaglutide)
  • Single flat price across all doses simplifies titration planning
  • Corporate address (St. Petersburg, FL) and customer-service phone published

Where it loses points

  • No LegitScript, NABP .pharmacy, or HIPAA badge on the home page
  • Pharmacy partner not named (only 'regulated FDA pharmacy partners')
  • State coverage list not published — can't verify all-50-state availability
  • Clinical care runs through MD Integrations, a shared third-party network used by many brands
  • No brand-name Wegovy or Zepbound option
FuturHealth

Graded #219 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard